ANX007 is a Potential Treatment for Geographic Atrophy, According to ARCHER Study

ARCHER study demonstrated that the antibody ANX007 was time and dose dependent, robust, and not dependent on lesion growth.

Related Keywords

California ,United States ,San Francisco ,American ,David Lally ,American Academy Of Ophthalmology ,New England ,New England Retina Consultants ,Geographic Atrophy Secondary ,Age Related Macular Degeneration ,Selective Classical Complement Inhibitor ,Annual American Academy ,